Eli Lilly and Company (NYSE:LLY) reported on Wednesday that U.S. FDA has permitted Cyramza (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. Eli Lilly and Company (NYSE:LLY) stock price closed at $66.99 with the total traded volume of 3.04 Million shares. Its price to sales ratio ended at 3.67. Its market capitalization is 71.652 Billion. The stock owned by the Financial Institutions was 76.30% while by insiders was 11.90%.Silver producer, Hecla Mining Co. (NYSE:HL) released on Wednesday that its Q3 net earnings to stockholders of $3.5M or $0.01 per share as compared with a loss of $8.6 million or $0.03 per share last year. Excluding items, adjusted loss for the quarter was $0.01 per share compared with a loss of $0.02 per share a year ago. Hecla Mining Co. (NYSE:HL) has the market capitalization of 713.0 Million. Shares of firm moved down -5.99% to close at $2.04 with the total traded volume of 15.41 Million. The firm has current ratio of 2.40 for the most recent quarter.Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released on Wednesday that the U.S. Food and Drug Administration has granted orphan drug designation to their investigational drug candidate MM-141 for the treatment of pancreatic cancer. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) begun last trade with a price of $9.00 and throughout the trading session climbed at a high of $9.10. The day-trade ended with -5.76% to $8.35. The stock is going forward to its 52 week low with 307.32% and lagging behind from its 52 week high price with -12.93%. MACK last month stock price volatility remained 6.66%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
